Scripps Research Chemistry Professor Matthew Disney and graduate student Matthew Costales show how an RNA binding molecule can make a breast cancer cell sensitive to Herceptin.
A new study from the lab of Scripps Research chemist Matthew D. Disney, Ph.D., suggests that in the future, that might not be the final word on the matter. Writing in the Journal of the American Chemical Society, Disney's group describes shifting three different cancer cell lines from HER2-negative status to HER2-positive status with the addition of a selective micro-RNA binding molecule they referred to as TGP-515.
It's a revolutionary idea, that a cancer's genotype might not have to be the limiting factor in its range of targeted treatment options. However, this is just a first step in a long series of work ahead to enable the technology to benefit cancer patients.
Read more information, visit: Medicalxpress
Medical Xpress is a web-based medical and health news service that is part of the renowned Science X network.
Read more related topics: